🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Standard maintenance for squamous NSCLC

Found 20 matching trials

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

PHASE2

Open label multicentric randomized phase II trial, using high throughput ge...

Status

Completed

Location

Centre Hospitalier Henri Duffau

Start Date

2014-04-23

Trial ID

NCT02117167

Treatments Being Tested

AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard maintenance for squamous NSCLC Pemetrexed Durvalumab savolitinib Olaparib

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

PHASE3

This is a randomized, open-label, multi-center, global, Phase III study to ...

Status

Active Not Recruiting

Location

Research Site

Start Date

2017-06-01

Trial ID

NCT03164616

Treatments Being Tested

Durvalumab Tremelimumab Abraxane + carboplatin Gemcitabine + cisplatin Gemcitabine + carboplatin Pemetrexed + carboplatin Pemetrexed + cisplatin

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

PHASE3

Maintenance treatment of advanced stage squamous cell NSCLC. Phase III, ra...

Status

Completed

Location

Clearview Cancer Institute Oncology Specialties, P.C

Start Date

2014-02-11

Trial ID

NCT02027428

Treatments Being Tested

Abraxane (Induction)Carboplatin (Induction)Abraxane (Maintenance)Best Supportive Care (Maintenance)Abraxane (Induction)Carboplatin (Induction)Best Supportive Care (Maintenance)

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE3

This is an international, randomized, open-label, Phase 3 study designed to...

Status

Terminated

Location

Hospital Britanico

Start Date

2020-07-24

Trial ID

NCT04222972

Treatments Being Tested

Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC

PHASE2

The purpose of this study is to test if low dose radiation, which is routin...

Status

Terminated

Location

NYU Langone Health

Start Date

2023-01-24

Trial ID

NCT05691829

Treatments Being Tested

Pembrolizumab Radiation Chemotherapy

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

PHASE2

Lung cancer is one of the malignant tumors with high morbidity and mortalit...

Status

Completed

Location

Shanghai pulmonary hospital, Tongji University

Start Date

2021-01-20

Trial ID

NCT04702009

Treatments Being Tested

Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

PHASE3

This randomized, open-label study will evaluate the efficacy and safety of ...

Status

Completed

Location

University of California San Diego

Start Date

2015-07-20

Trial ID

NCT02409342

Treatments Being Tested

Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody Carboplatin Cisplatin Gemcitabine Pemetrexed

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

PHASE3

First-line immunotherapy-based standard of care and local ablative treatmen...

Status

Recruiting

Location

Institut de Radiothérapie du Sud de l'Oise

Start Date

2025-09-09

Trial ID

NCT06840782

Treatments Being Tested

Radical local treatment SoC-based immunotherapy (+/- chemotherapy)

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

PHASE2

The purpose of this study, known as DISCERN, is to compare two different tr...

Status

Recruiting

Location

University of Alabama at Birmingham

Start Date

2025-05-30

Trial ID

NCT06364917

Treatments Being Tested

Pembrolizumab Carboplatin Paclitaxel Pemetrexed Nivolumab Ipilimumab

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

PHASE2

This is an open-label, non-randomised, phase II, multicenter clinical trial...

Status

Active Not Recruiting

Location

ICO Badalona, Hospital Germans Trias i Pujol

Start Date

2021-11-18

Trial ID

NCT05012254

Treatments Being Tested

Ipilimumab Nivolumab Carboplatin Cisplatin Paclitaxel Pemetrexed

Previous Next